448 research outputs found
An assessment of the efficiency of the information system of design-and-survey organizations based on the analysis of the information capacity of projects implemented
The article features an analysis of the global and Russian construction markets and reflects the place of design-and-survey organizations in the development of this industry. Relying on the findings of a critical analysis of existing approaches to analyzing information costs, the authors bring forward a methodology for assessing the efficiency of the information system of a design-and-survey organization based on the analysis of the information capacity of projects implemented. The article introduces the term "information capacity". The authors have worked out a classification for information costs arising in developing a project. The testing of the methodology was conducted through the example of the activity of the design-and-survey organization JSC Institute "Kazan Promstroiproyekt" (The Republic of Tatarstan (the Russian Federation)). The authors have brought forward recommendations on boosting the efficiency of the organization's information system. Β© IDOSI Publications, 2014
ΠΠ‘Π’ΠΠ ΠΠ― Π‘ΠΠΠΠΠΠΠ― Π Π ΠΠΠΠΠ’ΠΠ― Π ΠΠ‘Π‘ΠΠΠ‘ΠΠΠΠ ΠΠΠ£Π§ΠΠΠΠ ΠΠΠΠΠ¦ΠΠΠ‘ΠΠΠΠ ΠΠΠ©ΠΠ‘Π’ΠΠ Π’ΠΠ ΠΠΠΠΠ’ΠΠ
The history of a scientific medical society of physicians in Russia and Tomsk. Describe the contribution of outstanding scientists and clinicians in the development of society practitioners, as well as large schools known not only in Russia but also abroad. Outlines the achievements of the last decade.ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π° ΠΈΡΡΠΎΡΠΈΡ ΡΠΎΠ·Π΄Π°Π½ΠΈΡ Π½Π°ΡΡΠ½ΠΎΠ³ΠΎ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠ³ΠΎ ΠΎΠ±ΡΠ΅ΡΡΠ²Π° ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΎΠ² Π² Π ΠΎΡΡΠΈΠΈ ΠΈ Π³. Π’ΠΎΠΌΡΠΊΠ΅. ΠΠΏΠΈΡΠ°Π½ Π²ΠΊΠ»Π°Π΄ Π²ΡΠ΄Π°ΡΡΠΈΡ
ΡΡ ΡΡΠ΅Π½ΡΡ
-ΠΊΠ»ΠΈΠ½ΠΈΡΠΈΡΡΠΎΠ² Π² ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ ΠΎΠ±ΡΠ΅ΡΡΠ²Π° ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΎΠ², Π° ΡΠ°ΠΊΠΆΠ΅ ΠΊΡΡΠΏΠ½ΡΡ
Π½Π°ΡΡΠ½ΡΡ
ΡΠΊΠΎΠ», ΠΈΠ·Π²Π΅ΡΡΠ½ΡΡ
Π½Π΅ ΡΠΎΠ»ΡΠΊΠΎ Π² Π ΠΎΡΡΠΈΠΈ, Π½ΠΎ ΠΈ Π·Π° ΡΡΠ±Π΅ΠΆΠΎΠΌ. ΠΠ±ΠΎΠ·Π½Π°ΡΠ΅Π½Ρ Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΡ ΠΏΠΎΡΠ»Π΅Π΄Π½Π΅Π³ΠΎ Π΄Π΅ΡΡΡΠΈΠ»Π΅ΡΠΈΡ
The role of human and microbial metabolites of triptophane in severe diseases and critical ill (review)
The growing interest to metabolites circulating in the blood is associated with the accumulation of factual material on the involvement of low-molecular compounds in the development of a number of serious diseases. This review reveals the effect of a whole class of chemical compounds tryptophan metabolites on various pathological processes. The following keywords were used to find the publications in the PubMed database for the last 10 years: names of natural indole compounds, methods for their detection, nosology of diseases and critical illness . The data are presented in sections, with the studies of tryptophan metabolites in a variety of disease groups, such as cancer, cardiovascular disease, kidney disease, bowel, mental disorders, atherosclerosis, etc. A particular attention is paid to the role of indole compounds that enter the systemic circulation as a result of microbial biotransformation of tryptophan, serotonin and other indole metabolites, which can be attributed to the common metabolites of humans and microbiota. The most interesting clinical studies are summarized in the tables and figures. A number of indole metabolites are considered as potential biomarkers. The authors of the review substantiate the metabolomic approach to the study of a number of oncological, septic, mental and other intractable diseases, which opens up new possibilities of influence on the pathological process by targeted regulation in the metabolome/microbiome system
ΠΡΠΈΠΎΡΡΠΎΠΏΠ½Π°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ COVID-19: ΠΊΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΈ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Ρ
The COVID-19 outbreak started in December 2019 in China has spread over all countries of the world within few month acquiring a pandemic nature, the incident population counting millions. The pathogenic mechanisms of the new coronaviral infection caused by never-before-seen virus SARS-CoV2 are yet to be studied. Various drugs are used for COVID-19 treatment and guidelines are continuously revised as new experience is acquired. In the current pandemic situation, it is important to provide specialists with latest information concerning efficacy and safety drugs for COVID-19 patients and promising research in this field.The purpose of the review is to critically analyze published data on outcomes of COVID-19 treatment with various drugs including potentially promising drugs.The search has been carried out through such databases as PubMed, Scopus, Cyberleninka, https://www.globalclinicaltrialsdata.com, https://clinicaltrials.gov, Cochrane Library; mostly, randomized clinical trials-2020 and papers dedicated to candidate drugs have been considered. The paper is structured based on the drugβs action mechanism and contains parts dedicated to antiviral, immunomodulatory, and antibacterial therapies. Looking for a new promising target in COVID-19 treatment, the authors focus their attention on matrix metalloproteinases (MMP), which abundance results in the destruction of extracellular matrix, epithelial and endothelial basal membranes and leads to secondary lung tissue injury. The paper provides a theoretic justification of MMP inhibitor use by an example of doxycycline and offers an efficacy study protocol for the new approach to COVID-19 therapy.Conclusion: as of now, there are no drugs which efficacy for COVID 19 has been proven. Drugs possessing multiple mechanisms of action are employed beside their specified indications, often in combinations; in this situation, additive side effects with adverse consequences for the patient can hardly be avoided. Administration of drugs with unproven efficacy may be justified only in clinical trials followed by subsequent analysis and publication of findings demonstrating that in case of success, recommendations for a majority of COVID-19 patients could be confidently issued.ΠΠΏΠΈΠ΄Π΅ΠΌΠΈΡ COVID-19, Π½Π°ΡΠ°Π²ΡΠ°ΡΡΡ Π² Π΄Π΅ΠΊΠ°Π±ΡΠ΅ 2019 Π³ΠΎΠ΄Π° Π² ΠΠΈΡΠ°Π΅, Π·Π° Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΎ ΠΌΠ΅ΡΡΡΠ΅Π² ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½ΠΈΠ»Π°ΡΡ Π½Π° Π²ΡΠ΅ ΡΡΡΠ°Π½Ρ ΠΌΠΈΡΠ°, ΠΏΡΠΈΠ½ΡΠ² Ρ
Π°ΡΠ°ΠΊΡΠ΅Ρ ΠΏΠ°Π½Π΄Π΅ΠΌΠΈΠΈ, ΡΠΈΡΠ»ΠΎ Π·Π°Π±ΠΎΠ»Π΅Π²ΡΠΈΡ
ΠΈΡΡΠΈΡΠ»ΡΠ΅ΡΡΡ ΠΌΠΈΠ»Π»ΠΈΠΎΠ½Π°ΠΌΠΈ. ΠΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΡ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π° Π½ΠΎΠ²ΠΎΠΉ ΠΊΠΎΡΠΎΠ½Π°Π²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ, Π²ΡΠ·Π²Π°Π½Π½ΠΎΠΉ Π½Π΅ΠΈΠ·Π²Π΅ΡΡΠ½ΡΠΌ ΡΠ°Π½Π΅Π΅ Π²ΠΈΡΡΡΠΎΠΌ SARS-CoV2, ΠΎΡΡΠ°ΡΡΡΡ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ ΠΈΠ·ΡΡΠ΅Π½Π½ΡΠΌΠΈ. ΠΠ»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ COVID-19 ΠΏΡΠΈΠΌΠ΅Π½ΡΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ ΡΠ°Π·Π½ΡΡ
Π³ΡΡΠΏΠΏ, ΠΏΠΎ ΠΌΠ΅ΡΠ΅ ΠΏΠΎΡΠ²Π»Π΅Π½ΠΈΡ ΠΎΠΏΡΡΠ° ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΈ ΡΠ΅Π³ΡΠ»ΡΡΠ½ΠΎ ΠΏΠ΅ΡΠ΅ΡΠΌΠ°ΡΡΠΈΠ²Π°ΡΡΡΡ. Π ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΡΠ΅ΠΊΡΡΠ΅ΠΉ ΠΏΠ°Π½Π΄Π΅ΠΌΠΈΠΈ Π²Π°ΠΆΠ½ΠΎ ΠΏΡΠ΅Π΄ΠΎΡΡΠ°Π²ΠΈΡΡ ΡΠΏΠ΅ΡΠΈΠ°Π»ΠΈΡΡΠ°ΠΌ Π°ΠΊΡΡΠ°Π»ΡΠ½ΡΡ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡ ΠΎΠ± ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ Π»Π΅ΡΠ΅Π±Π½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ², ΠΏΡΠΈΠΌΠ΅Π½ΡΠ΅ΠΌΡΡ
Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ COVID-19, ΠΈ ΠΎ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡΡ
Π² ΡΡΠΎΠΉ ΠΎΠ±Π»Π°ΡΡΠΈ.Β Π¦Π΅Π»Ρ ΠΎΠ±Π·ΠΎΡΠ° β ΠΊΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΎΠΏΡΠ±Π»ΠΈΠΊΠΎΠ²Π°Π½Π½ΡΡ
ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² Π»Π΅ΡΠ΅Π½ΠΈΡ COVID-19 Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
Π³ΡΡΠΏΠΏ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Π΄Π»Ρ Π²ΡΠ±ΠΎΡΠ° Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
ΡΡΠ΅Π΄ΡΡΠ².ΠΠΎΠΈΡΠΊ ΠΈΡΡΠΎΡΠ½ΠΈΠΊΠΎΠ² ΠΏΡΠΎΠ²Π΅Π»ΠΈ ΠΏΠΎ Π±Π°Π·Π°ΠΌ Π΄Π°Π½Π½ΡΡ
PubMed, Scopus, Cyberleninka, Clinical Trials, Cochrane Library ΠΈ Π΄Ρ., ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°Π»ΠΈ ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ ΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ 2020 Π³ΠΎΠ΄Π°, Π° ΡΠ°ΠΊΠΆΠ΅ ΡΠ°Π±ΠΎΡΡ ΠΏΠΎ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ²-ΠΏΡΠ΅ΡΠ΅Π½Π΄Π΅Π½ΡΠΎΠ². ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΡΡΠ°ΡΡΠΈ ΡΡΡΡΠΊΡΡΡΠΈΡΠΎΠ²Π°Π½ ΠΏΠΎ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΡ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ², ΡΠΎΠ΄Π΅ΡΠΆΠΈΡ ΡΠ°Π·Π΄Π΅Π»Ρ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉ, ΠΈΠΌΠΌΡΠ½ΠΎΠΌΠΎΠ΄ΡΠ»ΠΈΡΡΡΡΠ΅ΠΉ, Π°Π½ΡΠΈΠ±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. Π ΠΏΠΎΠΈΡΠΊΠ΅ Π½ΠΎΠ²ΠΎΠΉ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΠΌΠΈΡΠ΅Π½ΠΈ Π² Π»Π΅ΡΠ΅Π½ΠΈΠΈ COVID-19 ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠΈΡΠΎΠ²Π°Π»ΠΈ Π²Π½ΠΈΠΌΠ°Π½ΠΈΠ΅ Π½Π° ΠΌΠ°ΡΡΠΈΠΊΡΠ½ΡΡ
ΠΌΠ΅ΡΠ°Π»Π»ΠΎΠΏΡΠΎΡΠ΅ΠΈΠ½Π°Π·Π°Ρ
(ΠΠΠ ), ΠΈΠ·Π±ΡΡΠΎΠΊ ΠΊΠΎΡΠΎΡΡΡ
Π²Π΅Π΄Π΅Ρ ΠΊ ΡΠ°Π·ΡΡΡΠ΅Π½ΠΈΡ Π²Π½Π΅ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΌΠ°ΡΡΠΈΠΊΡΠ°, Π±Π°Π·Π°Π»ΡΠ½ΡΡ
ΠΌΠ΅ΠΌΠ±ΡΠ°Π½ ΡΠΏΠΈΡΠ΅Π»ΠΈΡ ΠΈ ΡΠ½Π΄ΠΎΡΠ΅Π»ΠΈΡ, ΡΠΏΠΎΡΠΎΠ±ΡΡΠ²ΡΠ΅Ρ Π²ΡΠΎΡΠΈΡΠ½ΠΎΠΌΡ ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡ Π»Π΅Π³ΠΎΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ. Π ΡΠ°Π±ΠΎΡΠ΅ ΡΠ΅ΠΎΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΈ ΠΎΠ±ΠΎΡΠ½ΠΎΠ²Π°Π»ΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠ² MMP Π½Π° ΠΏΡΠΈΠΌΠ΅ΡΠ΅ Π΄ΠΎΠΊΡΠΈΡΠΈΠΊΠ»ΠΈΠ½Π°, ΠΏΡΠ΅Π΄Π»ΠΎΠΆΠΈΠ»ΠΈ ΠΏΡΠΎΡΠΎΠΊΠΎΠ» ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π΄Π»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π½ΠΎΠ²ΠΎΠ³ΠΎ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄Π° ΠΊ Π»Π΅ΡΠ΅Π½ΠΈΡ COVID-19.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
ΡΡΠ΅Π΄ΡΡΠ² Ρ Π΄ΠΎΠΊΠ°Π·Π°Π½Π½ΠΎΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ COVID 19 Π² Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ Π½Π΅Ρ. ΠΡΠ΅ΠΏΠ°ΡΠ°ΡΡ Ρ ΡΠ°Π·Π½ΡΠΌΠΈ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΠ°ΠΌΠΈ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ ΠΏΡΠΈΠΌΠ΅Π½ΡΡΡΡΡ Π½Π΅ ΠΏΠΎ ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΈΡΠΌ, ΡΠ°ΡΡΠΎ Π² ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΡΡ
, Π² ΡΡΠΈΡ
ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΡΡΡΠ΄Π½ΠΎ ΠΈΠ·Π±Π΅ΠΆΠ°ΡΡ ΡΡΠΌΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΏΠΎΠ±ΠΎΡΠ½ΡΡ
ΡΡΡΠ΅ΠΊΡΠΎΠ² Ρ Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΌΠΈ ΠΏΠΎΡΠ»Π΅Π΄ΡΡΠ²ΠΈΡΠΌΠΈ Π΄Π»Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°. ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Ρ Π½Π΅Π΄ΠΎΠΊΠ°Π·Π°Π½Π½ΠΎΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ ΠΎΠΏΡΠ°Π²Π΄Π°Π½ΠΎ Π»ΠΈΡΡ Π² ΡΠ°ΠΌΠΊΠ°Ρ
ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Ρ ΠΏΠΎΡΠ»Π΅Π΄ΡΡΡΠΈΠΌ Π°Π½Π°Π»ΠΈΠ·ΠΎΠΌ ΠΈ ΠΏΡΠ±Π»ΠΈΠΊΠ°ΡΠΈΠ΅ΠΉ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ², ΡΡΠΎΠ±Ρ Π² ΡΠ»ΡΡΠ°Π΅ ΡΡΠΏΠ΅Ρ
Π° Ρ ΡΠ²Π΅ΡΠ΅Π½Π½ΠΎΡΡΡΡ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄ΠΎΠ²Π°ΡΡ ΠΈΡ
Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ COVID-19. ΠΠ»ΡΡΠ΅Π²ΡΠ΅ ΡΠ»ΠΎΠ²Π°: COVID-19; ΠΏΡΠΎΡΠΈΠ²ΠΎΠΌΠ°Π»ΡΡΠΈΠΉΠ½ΡΠ΅ ΡΡΠ΅Π΄ΡΡΠ²Π°; ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΡ Π²ΠΈΡΡΡΠ½ΡΡ
ΠΏΡΠΎΡΠ΅Π°Π·; ΠΏΡΠΎΡΠΈΠ²ΠΎΠΏΠ°ΡΠ°Π·ΠΈΡΠ°ΡΠ½ΡΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ; ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΡ ΠΈΠ½ΡΠ΅ΡΠ»Π΅ΠΉΠΊΠΈΠ½ΠΎΠ²; ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΡ ΡΠ½ΡΡ-ΠΊΠΈΠ½Π°Π·; ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠΎΠ½Ρ; ΠΏΠ»Π°Π·ΠΌΠ° ΡΠ΅ΠΊΠΎΠ½Π²Π°Π»Π΅ΡΡΠ΅Π½ΡΠΎΠ²; ΠΊΠΎΡΡΠΈΠΊΠΎΡΡΠ΅ΡΠΎΠΈΠ΄Ρ; ΠΏΡΠΎΠΊΠ°Π»ΡΡΠΈΡΠΎΠ½ΠΈΠ½; Π°Π½ΡΠΈΠ±ΠΈΠΎΡΠΈΠΊΠΈ; Π½ΠΎΠ²Π°Ρ ΠΌΠΈΡΠ΅Π½Ρ; ΠΌΠ°ΡΡΠΈΠΊΡΠ½ΡΠ΅ ΠΌΠ΅ΡΠ°Π»Π»ΠΎΠΏΡΠΎΡΠ΅ΠΈΠ½Π°Π·Ρ, Π΄ΠΎΠΊΡΠΈΡΠΈΠΊΠ»ΠΈΠ½
Π‘ΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½Π°Ρ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ° ΡΡΠ΅ΠΏΠ΅Π½ΠΈ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ ΡΡΠ°Π΄ΠΈΠΈ ΡΠΈΠ±ΡΠΎΠ·Π° ΠΏΡΠΈ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΌ Π²ΠΈΡΡΡΠ½ΠΎΠΌ Π³Π΅ΠΏΠ°ΡΠΈΡΠ΅ Π‘
A comparison of degrees necroinflammatory activity and fibrosis stages in 433 biopsy specimens of patients with chronic viral hepatitis C (monoinfection and in combination with drug abuse, alcoholic disease, chronic opisthorchosis). Found that ethyl alcohol is the greatest character weights of alteration and severity of multiple sclerosis with HCV-infection. Drug abuse enhances fibrosis in the liver, but no histological activity, and only in comparison with mono-HCV infection. Opisthorchosis defines weakly expressed necroinflammatory and sclerotic changes with (by) HCV-infection.ΠΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ ΡΡΠ΅ΠΏΠ΅Π½Π΅ΠΉ Π½Π΅ΠΊΡΠΎΠ·ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ ΡΡΠ°Π΄ΠΈΠΈ ΡΠΈΠ±ΡΠΎΠ·Π° Π² Π±ΠΈΠΎΠΏΡΠ°ΡΠ°Ρ
433 Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΡΠΈ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΌ Π²ΠΈΡΡΡΠ½ΠΎΠΌ Π³Π΅ΠΏΠ°ΡΠΈΡΠ΅ Π‘ (Π₯ΠΠΠ‘) (ΠΌΠΎΠ½ΠΎΠΈΠ½ΡΠ΅ΠΊΡΠΈΡ, ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ Ρ ΠΎΠΏΠΈΠΉΠ½ΠΎΠΉ Π½Π°ΡΠΊΠΎΠΌΠ°Π½ΠΈΠ΅ΠΉ, Π°Π»ΠΊΠΎΠ³ΠΎΠ»ΡΠ½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ, ΠΎΠΏΠΈΡΡΠΎΡΡ
ΠΎΠ·ΠΎΠΌ). Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ ΡΡΠΈΠ»ΠΎΠ²ΡΠΉ Π°Π»ΠΊΠΎΠ³ΠΎΠ»Ρ Π² Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠ΅ΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΡΡΠΆΠ΅Π»ΡΠ΅Ρ Ρ
Π°ΡΠ°ΠΊΡΠ΅Ρ Π°Π»ΡΡΠ΅ΡΠ°ΡΠΈΠ²Π½ΡΡ
ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ ΠΈ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΡ ΡΠΊΠ»Π΅ΡΠΎΠ·Π° ΠΏΡΠΈ HCV-ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ. ΠΠΏΠΈΠΉΠ½Π°Ρ Π½Π°ΡΠΊΠΎΠΌΠ°Π½ΠΈΡ ΡΡΠΈΠ»ΠΈΠ²Π°Π΅Ρ ΡΠΈΠ±ΡΠΎΠ· Π² ΠΏΠ΅ΡΠ΅Π½ΠΈ, Π½ΠΎ Π½Π΅ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΡΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΈ ΡΠΎΠ»ΡΠΊΠΎ Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ Ρ ΠΌΠΎΠ½ΠΎΠΈΠ½ΡΠ΅ΠΊΡΠΈΠ΅ΠΉ Π₯ΠΠΠ‘. ΠΠΏΠΈΡΡΠΎΡΡ
ΠΎΠ·Π½Π°Ρ ΠΈΠ½Π²Π°Π·ΠΈΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ΅Ρ ΡΠ»Π°Π±ΡΡ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΡ Π½Π΅ΠΊΡΠΎΠ·ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΠΈ ΡΠΊΠ»Π΅ΡΠΎΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ ΠΏΡΠΈ HCV-ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ
ΠΠ°ΡΠ΅ΡΡΠ²ΠΎ ΠΆΠΈΠ·Π½ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ ΡΠΈΡΡΠΎΠ·ΠΎΠΌ ΠΏΠ΅ΡΠ΅Π½ΠΈ Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ ΡΠΎΠ½ΡΡΠ° Π²Π΅Π³Π΅ΡΠ°ΡΠΈΠ²Π½ΠΎΠΉ Π½Π΅ΡΠ²Π½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ
At present, medical attention is paid to the quality of life for patients. The dependence between the quality of life and the course of the disease, personality patients characteristics. In the conducted study involved 139 patients with cirrhosis of the liver. With the help of questionnaires, self-administered by patients, assessed the quality of life depending on the tone of the autonomic nervous system. As a result of supervision it is established that the vegetative disbalance at sick of a cirrhosis with prevalence of parasympathetic influences worsens indicators of quality of life in spheres of vigor, painful sensations and emotional reactions.Π Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ Π² ΠΌΠ΅Π΄ΠΈΡΠΈΠ½Π΅ Π±ΠΎΠ»ΡΡΠΎΠ΅ Π²Π½ΠΈΠΌΠ°Π½ΠΈΠ΅ ΡΠ΄Π΅Π»ΡΠ΅ΡΡΡ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΆΠΈΠ·Π½ΠΈ (ΠΠ) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². ΠΡΡΠ»Π΅Π΄ΡΠ΅ΡΡΡ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΡ ΠΌΠ΅ΠΆΠ΄Ρ ΠΠ ΠΈ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ΠΌ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΡΠΌΠΈ Π»ΠΈΡΠ½ΠΎΡΡΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°. Π ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π½ΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΠΏΡΠΈΠ½ΠΈΠΌΠ°Π»ΠΈ ΡΡΠ°ΡΡΠΈΠ΅ 139 Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠΈΡΡΠΎΠ·ΠΎΠΌ ΠΏΠ΅ΡΠ΅Π½ΠΈ (Π¦Π). ΠΡΠΈ ΠΏΠΎΠΌΠΎΡΠΈ Π°Π½ΠΊΠ΅Ρ, ΡΠ°ΠΌΠΎΡΡΠΎΡΡΠ΅Π»ΡΠ½ΠΎ Π·Π°ΠΏΠΎΠ»Π½ΡΠ΅ΠΌΡΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌΠΈ, ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΎΡΡ ΠΠ Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ ΡΠΎΠ½ΡΡΠ° Π²Π΅Π³Π΅ΡΠ°ΡΠΈΠ²Π½ΠΎΠΉ Π½Π΅ΡΠ²Π½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ. Π ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ΅ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Π²Π΅Π³Π΅ΡΠ°ΡΠΈΠ²Π½ΡΠΉ Π΄ΠΈΡΠ±Π°Π»Π°Π½Ρ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠΈΡΡΠΎΠ·ΠΎΠΌ ΠΏΠ΅ΡΠ΅Π½ΠΈ Ρ ΠΏΡΠ΅ΠΎΠ±Π»Π°Π΄Π°Π½ΠΈΠ΅ΠΌ ΠΏΠ°ΡΠ°ΡΠΈΠΌΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π²Π»ΠΈΡΠ½ΠΈΠΉ ΡΡ
ΡΠ΄ΡΠ°Π΅Ρ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΠΠ Π² ΡΡΠ΅ΡΠ°Ρ
ΡΠ½Π΅ΡΠ³ΠΈΡΠ½ΠΎΡΡΠΈ, Π±ΠΎΠ»Π΅Π²ΡΡ
ΠΎΡΡΡΠ΅Π½ΠΈΠΉ ΠΈ ΡΠΌΠΎΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΡΠ΅Π°ΠΊΡΠΈΠΉ
ΠΠΠΠΠΠ-Π‘Π’Π ΠΠ’ΠΠΠΠ ΠΠΠΠ¬ΠΠ«Π₯ Π₯Π ΠΠΠΠ§ΠΠ‘ΠΠΠΠ ΠΠΠ‘ΠΠΠΠΠ’ΠΠΠ¬ΠΠ«ΠΠ ΠΠΠΠΠΠΠΠΠΠΠ―ΠΠ ΠΠΠ¨ΠΠ§ΠΠΠΠ
Research aim was definition of prevailing coping strategies of patients with inflammatory bowel diseases of in comparison with healthy people. 49 patients with ulcer colitis are surveyed. Coping strategies were defined by means of E.Heim's test. Patients with ulcerative colitis more often than healthy used to maladaptive coping strategies in the emotional and cognitive sphere that can testify to violation of psychological adaptation.Β Π¦Π΅Π»ΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ²Π»ΡΠ»ΠΎΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΡΠ΅ΠΎΠ±Π»Π°Π΄Π°ΡΡΠΈΡ
Π²Π°ΡΠΈΠ°Π½ΡΠΎΠ² ΡΠΎΠ²Π»Π°Π΄Π°ΡΡΠ΅Π³ΠΎ ΠΏΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ ΠΊΠΈΡΠ΅ΡΠ½ΠΈΠΊΠ° Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ ΡΠΎ Π·Π΄ΠΎΡΠΎΠ²ΡΠΌΠΈ Π»ΡΠ΄ΡΠΌΠΈ. ΠΠ±-ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΎ 49 Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ·Π²Π΅Π½Π½ΡΠΌ ΠΊΠΎΠ»ΠΈΡΠΎΠΌ. ΠΠΎΠΏΠΈΠ½Π³-ΡΡΡΠ°ΡΠ΅Π³ΠΈΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈΡΡ ΠΏΡΠΈ ΠΏΠΎΠΌΠΎΡΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠΈ Π. Π₯Π΅ΠΉΠΌΠ°. ΠΠ°ΡΠΈΠ΅Π½ΡΡ Ρ ΡΠ·Π²Π΅Π½Π½ΡΠΌ ΠΊΠΎΠ»ΠΈΡΠΎΠΌ ΡΠ°ΡΠ΅, ΡΠ΅ΠΌ Π·Π΄ΠΎΡΠΎΠ²ΡΠ΅ Π»ΡΠ΄ΠΈ, Π²ΡΠ±ΠΈΡΠ°ΡΡ Π½Π΅Π°Π΄Π°ΠΏΡΠΈΠ²Π½ΡΠ΅ ΡΡΡΠ°ΡΠ΅Π³ΠΈΠΈ ΡΠΎΠ²Π»Π°Π΄Π°Π½ΠΈΡ Π² ΡΠΌΠΎΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠΉ ΠΈ ΠΊΠΎΠ³Π½ΠΈΡΠΈΠ²Π½ΠΎΠΉ ΡΡΠ΅ΡΠ΅, ΡΡΠΎ ΠΌΠΎΠΆΠ΅Ρ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΠΎΠ²Π°ΡΡ ΠΎ Π½Π°-ΡΡΡΠ΅Π½ΠΈΠΈ ΠΏΡΠΈΡ
ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°Π΄Π°ΠΏΡΠ°ΡΠΈΠΈ
- β¦